Inhaler Devices for Patients with COPD

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. 2011, December. http://www.goldcopd.org (accessed 2012, June 29).
   Google Scholar
• COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994 May; 105(5):1411–1419.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008 Oct 9; 359(15):1543–1554.
   PubMed Web of Science ®Google Scholar
• Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009 Oct 3; 374(9696):1171–1178.
   PubMed Web of Science ®Google Scholar
• Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008 Aug 15; 178(4):332–338.
   PubMed Web of Science ®Google Scholar
• Kesten S, Casaburi R, Kukafka D, Cooper CB. Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis 2008; 3(1):127–136.
   PubMedGoogle Scholar
• Pasqua F, Biscione G, Crigna G, Auciello L, Cazzola M. Combining triple therapy and pulmonary rehabilitation in patients with advanced COPD: A pilot study. Respir Med 2010 Mar; 104(3):412–417.
   PubMed Web of Science ®Google Scholar
• Ruffin RE, Montgomery JM, Newhouse MT. Site of beta-adrenergic receptors in the respiratory tract: use of fenoterol administered by two methods. Chest 1978 Sep; 74(3):256–260.
   PubMed Web of Science ®Google Scholar
• Davies DS. Pharmacokinetics of inhaled substances. Postgrad Med J 1975; 51(7 Suppl):69–75.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Basbaum CB, Nadel JA. Autoradiographic localization of autonomic receptors in airway smooth muscle. Marked differences between large and small airways. Am Rev Respir Dis 1983 Jun; 127(6):758–762.
   PubMed Web of Science ®Google Scholar
• Hughes JA, Tobin MJ, Bellamy D, Hutchison DC. Effects of ipratropium bromide and fenoterol aerosols in pulmonary emphysema. Thorax 1982 Sep; 37(9):667–670.
   PubMed Web of Science ®Google Scholar
• Adcock IM, Gilbey T, Gelder CM, Chung KF, Barnes PJ. Glucocorticoid receptor localization in normal and asthmatic lung. Am J Respir Crit Care Med 1996 Sep; 154(3 Pt 1):771–782.
   PubMed Web of Science ®Google Scholar
• Pavia D, Thomson M, Shannon HS. Aerosol inhalation and depth of deposition in the human lung. The effect of airway obstruction and tidal volume inhaled. Arch Environ Health 1977 May-Jun; 32(3):131–137.
   PubMed Web of Science ®Google Scholar
• Olséni L, Palmer J, Wollmer P. Quantitative evaluation of aerosol deposition pattern in the lung in patients with chronic bronchitis. Physiol Meas 1994 Feb; 15(1):41–48.
   PubMed Web of Science ®Google Scholar
• Derom E, Strandgården K, Schelfhout V, Borgström L, Pauwels R. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD. Respir Med 2007 Sep; 101(9):1931–1941.
   PubMed Web of Science ®Google Scholar
• Newman SP. Aerosol deposition considerations in inhalation therapy. Chest 1985 Aug; 88(2 Suppl):152S–160S.
   PubMed Web of Science ®Google Scholar
• Zanen P, Go LT, Lammers JW. Optimal particle size for β2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 1996 Oct; 51(10):977–980.
   PubMed Web of Science ®Google Scholar
• Rau JL. The inhalation of drugs: advantages and problems. Respir Care 2005 Mar; 50(3):367–382.
   Google Scholar
• Rubin BK. Air and soul: the science and application of aerosol therapy. Respir Care 2010 Jul; 55(7):911–921.
   PubMed Web of Science ®Google Scholar
• Rubin BK, Kelly HW. The impact of drug delivery devices in asthma management. J Respir Dis 2002; 4(Suppl):S36–S43.
   Google Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003 Dec; 56(6):600–612.
   PubMed Web of Science ®Google Scholar
• Hochrainer D, Hölz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med 2005 Fall; 18(3):273–282.
   PubMedGoogle Scholar
• Newman SP, Clarke SW. Therapeutic aerosols 1−physical and practical considerations. Thorax 1983 Dec; 38(12):881–886.
   PubMed Web of Science ®Google Scholar
• Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids: Does it matter? J Allergy Clin Immunol 2009 Dec; 124(6 Suppl):S88–S93.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA News Release. Asthma and COPD inhalers that contain ozone-depleting CFCs to be phased out; alternative treatments available. 2010, Apr 13. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm208302.htm (accessed 2012, June 29).
   Google Scholar
• United Nations Environment Programme. The Montreal Protocol on Substances that Deplete the Ozone Layer. 2000 Nairobi, Kenya: United Nations Environment Programme. http://www.unep.org/ozone/Montreal-Protocol/Montreal-Protocol2000.shtml (accessed 2012, July 1).
   Google Scholar
• Hendeles L, Colice GL, Meyer RJ. Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants. N Engl J Med 2007 Mar 29; 356(13):1344–1351.
   PubMed Web of Science ®Google Scholar
• Vincken W, Dekhuijzen PR, Barnes P. The ADMIT series − Issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD. Prim Care Respir J 2010 Mar; 19(1):10–20.
   Google Scholar
• Broeders ME, Sanchis J, Levy ML, Crompton GK, Dekhuijzen PN. The ADMIT series−issues in inhalation therapy. 2. Improving technique and clinical effectiveness. Prim Care Respir J 2009 Jun; 18(2):76–82.
   PubMedGoogle Scholar
• Barker DJ, Godfrey KM, Fall C, Osmond C, Winter PD, Shaheen SO. Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. BMJ 1991 Sep 21; 303(6804):671–675.
   PubMed Web of Science ®Google Scholar
• Britton JR, Pavord ID, Richards KA, Knox AJ, Wisniewski AF, Lewis SA, Tattersfield AE, Weiss ST. Dietary antioxidant vitamin intake and lung function in the general population. Am J Respir Crit Care Med 1995 May; 151(5):1383–1387.
   PubMed Web of Science ®Google Scholar
• Kaplan A, Cosentino L. α1-antitrypsin deficiency: forgotten etiology. Can Fam Physician 2010 Jan; 56(1):19–24.
   PubMed Web of Science ®Google Scholar
• Kaplan A, Hernandez P, O'Donnell D. Less smoke, more fire: What's new for you in the latest COPD guidelines? Can Fam Physician 2008 May; 54(5):737–739.
   PubMed Web of Science ®Google Scholar
• Burrows B, Knudson RJ, Lebowitz MD. The relationship of childhood respiratory illness to adult obstructive airway disease. Am Rev Respir Dis 1977 May; 115(5):751–760.
   PubMed Web of Science ®Google Scholar
• Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009 Aug 29; 374(9691):733–743.
   PubMed Web of Science ®Google Scholar
• Buist AS, Vollmer WM, Sullivan SD, Weiss KB, Lee TA, Menezes AM, Crapo RO, Jensen RL, Burney PG. The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. COPD 2005 Jun; 2(2):277–283.
   PubMedGoogle Scholar
• Ramsey SD, Hobbs FD. Chronic obstructive pulmonary disease, risk factors, and outcome trials: comparisons with cardiovascular disease. Proc Am Thorac Soc 2006 Sep; 3(7):635–640.
   PubMedGoogle Scholar
• Raherison C, Girodet PO. Epidemiology of COPD. Eur Respir Rev 2009 Dec; 18(114):213–221.
   PubMedGoogle Scholar
• Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002 May; 121(5 Suppl):121S–126S.
   PubMed Web of Science ®Google Scholar
• Brown DW, Croft JB, Greenlund KJ, Giles WH. Trends in hospitalization with chronic obstructive pulmonary disease-United States, 1990–2005. COPD 2010 Feb; 7(1):59–62.
   Google Scholar
• Rau JL. Practical problems with aerosol therapy in COPD. Respir Care 2006 Feb; 51(2):158–172.
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002 Sep 1; 166(5):675–679.
   PubMed Web of Science ®Google Scholar
• James AL, Palmer LJ, Kicic E, Maxwell PS, Lagan SE, Ryan GF, Musk AW. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med 2005 Jan 15; 171(2):109–114.
   PubMed Web of Science ®Google Scholar
• Bauer A, McGlynn P, Bovet LL, Mims PL, Curry LA, Hanrahan JP. The influence of breathing pattern during nebulization on the delivery of arformoterol using a breath simulator. Respir Care 2009 Nov; 54(11):1488–1492.
   PubMed Web of Science ®Google Scholar
• Thorsson L, Geller D. Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: focus on budesonide. Respir Med 2005 Jul; 99(7):836–849.
   PubMed Web of Science ®Google Scholar
• Filuk R. Delivery system selection: clinical considerations. Am Health Drug Benefits 2008; 1(8S):13–17.
   Google Scholar
• Rau JL. Design principles of liquid nebulization devices currently in use. Respir Care 2002 Nov; 47(11):1257–1275.
   PubMedGoogle Scholar
• Atkins PJ. Dry powder inhalers: an overview. Respir Care 2005 Oct; 50(10):1304–1312.
   PubMedGoogle Scholar
• Anderson PJ. Delivery options and devices for aerosolized therapeutics. Chest 2001 Sep; 120(3 Suppl):89S–93S.
   PubMed Web of Science ®Google Scholar
• Anderson P. Use of Respimat Soft Mist inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis 2006; 1(3):251–259.
   PubMedGoogle Scholar
• Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med 2005 Fall; 18(3):264–272.
   PubMedGoogle Scholar
• Newman SP. Use of gamma scintigraphy to evaluate the performance of new inhalers. J Aerosol Med 1999; 12 Suppl 1:S25–S31.
   PubMedGoogle Scholar
• Restrepo RD, Alvarez MT, Wittnebel LD, Sorenson H, Wettstein R, Vines DL, Sikkema-Ortiz J, Gardner DD, Wilkins RL. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 2008; 3(3):371–384.
   PubMedGoogle Scholar
• Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998 Dec; 12(6):1346–1353.
   PubMed Web of Science ®Google Scholar
• Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, Smaldone GC, Guyatt G. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005 Jan; 127(1):335–371.
   PubMed Web of Science ®Google Scholar
• Press VG, Arora VM, Shah LM, Lewis SL, Ivy K, Charbeneau J, Badlani S, Nareckas E, Mazurek A, Krishnan JA. Misuse of respiratory inhalers in hospitalized patients with asthma or COPD. J Gen Intern Med 2011 Jun; 26(6):635–642.
   PubMed Web of Science ®Google Scholar
• Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration 2008; 75(1):18–25.
   PubMed Web of Science ®Google Scholar
• van Beerendonk I, Mesters I, Mudde AN, Tan TD. Assessment of the inhalation technique in outpatients with asthma or chronic obstructive pulmonary disease using a metered-dose inhaler or dry powder device. J Asthma 1998; 35(3):273–279.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Voshaar TH, Virchow JC. Inhaler choice in primary practice. Eur Respir Rev 2005; 14(96):117–122.
   Google Scholar
• Hess D, Fisher D, Williams P, Pooler S, Kacmarek RM. Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 1996 Aug; 110(2):498–505.
   PubMed Web of Science ®Google Scholar
• Terzano C, Petroianni A, Parola D, Ricci A. Compressor/nebulizers differences in the nebulization of corticosteroids. The CODE study (Corticosteroids and Devices Efficiency). Eur Rev Med Pharmacol Sci 2007 Jul-Aug; 11(4):225–237.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Klein GL, Colman SS, Zayed H, Schonfeld WH. Comparing COPD treatment: nebulizer, metered dose inhaler, and concomitant therapy. Am J Med 2007 May; 120(5):435–441.
   PubMed Web of Science ®Google Scholar
• Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care 2005 Oct; 50(10):1313–1321.
   PubMedGoogle Scholar
• Melani AS, Canessa P, Coloretti I, Deangelis G, Detullio R, Deldonno M, Giacobbe R, Scarlato I, Serafini A, Barbato N, Vaghi A, Sestini P. Inhaler mishandling is very common in patients with chronic airflow obstruction and long-term home nebuliser use. Respir Med 2012 May; 106(5):668–676.
   PubMed Web of Science ®Google Scholar
• Dhand R, Dolovich M, Chipps B, T RM, Restrepo R, Rosen Farrar J. The role of nebulized therapy in the management of COPD: Evidence and recommendations. COPD 2012 Feb; 9(1):58–72.
   PubMedGoogle Scholar
• Suarez S, Hickey AJ. Drug properties affecting aerosol behavior. Respir Care 2000 Jun; 45(6):652–666.
   PubMedGoogle Scholar
• Rubin BK, Durotoye L. How do patients determine that their metered-dose inhaler is empty? Chest 2004 Oct; 126(4):1134–1137.
   PubMed Web of Science ®Google Scholar
• Bell J, Newman S. The rejuvenated pressurised metered dose inhaler. Expert Opin Drug Deliv 2007 May; 4(3):215–234.
   PubMed Web of Science ®Google Scholar
• Cain WT, Oppenheimer JJ. The misconception of using floating patterns as an accurate means of measuring the contents of metered-dose inhaler devices. Ann Allergy Asthma Immunol 2001 Nov; 87(5):417–419.
   PubMed Web of Science ®Google Scholar
• Leach C. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol 1999 Dec; 104(6):S250–S252.
   PubMed Web of Science ®Google Scholar
• Zeidler M, Corren J. Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma. Treat Respir Med 2004; 3(1):35–44.
   PubMedGoogle Scholar
• Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest 2002 Aug; 122(2):510–516.
   PubMed Web of Science ®Google Scholar
• Cyr TD, Graham SJ, Li KY, Lovering EG. Low first-spray drug content in albuterol metered-dose inhalers. Pharm Res 1991 May; 8(5):658–660.
   PubMed Web of Science ®Google Scholar
• Graham SJ, Ormsby ED, Lovering EG. Single spray drug content in a metered-dose aerosol formulation and a collection scheme for content uniformity. Pharmacopeial Forum 1992; 18(6):4400–4403.
   Google Scholar
• Acerbi D, Brambilla G, Kottakis I. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology. Pulm Pharmacol Ther 2007; 20(3):290–303.
   PubMed Web of Science ®Google Scholar
• De Backer W, Devolder A, Poli G, Acerbi D, Monno R, Herpich C, Sommerer K, Meyer T, Mariotti F. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv 2010 Jun; 23(3):137–148.
   PubMed Web of Science ®Google Scholar
• Wilkes W, Fink J, Dhand R. Selecting an accessory device with a metered-dose inhaler: variable influence of accessory devices on fine particle dose, throat deposition, and drug delivery with asynchronous actuation from a metered-dose inhaler. J Aerosol Med 2001 Fall; 14(3):351–360.
   PubMedGoogle Scholar
• Devadason SG, Huang T, Walker S, Troedson R, Le Souëf PN. Distribution of technetium-99m-labelled QVAR delivered using an Autohaler device in children. Eur Respir J 2003 Jun; 21(6):1007–1011.
   PubMed Web of Science ®Google Scholar
• Roller CM, Zhang G, Troedson RG, Leach CL, Le Souëf PN, Devadason SG. Spacer inhalation technique and deposition of extrafine aerosol in asthmatic children. Eur Respir J 2007 Feb; 29(2):299–306.
   PubMed Web of Science ®Google Scholar
• Paterson IC, Crompton GK. Use of pressurised aerosols by asthmatic patients. Br Med J 1976 Jan 10; 1(6001):76–77.
   PubMed Web of Science ®Google Scholar
• Gayrard P, Orehek J. [Inadequate use of pressurized aerosols by asthmatic patients [author's transl] [Article in French]. Respiration 1980; 40(1):47–52.
   PubMed Web of Science ®Google Scholar
• Dompeling E, Van Grunsven PM, Van Schayck CP, Folgering H, Molema J, Van Weel C. Treatment with inhaled steroids in asthma and chronic bronchitis: long-term compliance and inhaler technique. Fam Pract 1992 Jun; 9(2):161–166.
   PubMed Web of Science ®Google Scholar
• Hilton S. An audit of inhaler technique among asthma patients of 34 general practitioners. Br J Gen Pract 1990 Dec; 40(341):505–506.
   PubMed Web of Science ®Google Scholar
• Nimmo CJ, Chen DN, Martinusen SM, Ustad TL, Ostrow DN. Assessment of patient acceptance and inhalation technique of a pressurized aerosol inhaler and two breath-actuated devices. Ann Pharmacother 1993 Jul–Aug; 27(7-8):922–927.
   PubMed Web of Science ®Google Scholar
• Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, Corrigan C, Levy M, Crompton GK. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008 Apr; 102(4):593–604.
   PubMed Web of Science ®Google Scholar
• Schulte M, Osseiran K, Betz R, Wencker M, Brand P, Meyer T, Haidl P. Handling of and preferences for available dry powder inhaler systems by patients with asthma and COPD. J Aerosol Med Pulm Drug Deliv 2008 Dec; 21(4):321–328.
   PubMed Web of Science ®Google Scholar
• Goodman DE, Israel E, Rosenberg M, Johnston R, Weiss ST, Drazen JM. The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am J Respir Crit Care Med 1994 Nov; 150(5 Pt 1):1256–1261.
   PubMed Web of Science ®Google Scholar
• Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003 Fall; 16(3):249–254.
   PubMedGoogle Scholar
• Khassawneh BY, Al-Ali MK, Alzoubi KH, Batarseh MZ, Al-Safi SA, Sharara AM, Alnasr HM. Handling of inhaler devices in actual pulmonary practice: metered-dose inhaler versus dry powder inhalers. Respir Care 2008 Mar; 53(3):324–328.
   PubMed Web of Science ®Google Scholar
• Voshaar T, App EM, Berdel D, Buhl R, Fischer J, Gessler T, Haidl P, Heyder J, Köhler D, Kohlhäufl M, Lehr CM, Lindemann H, Matthys H, Meyer T, Olschewski H, Paul KD, Rabe K, Raschke F, Scheuch G, Schmehl T, Schultze-Werninghaus G, Ukena D, Worth H. Recommendations for the choice of inhalatory systems for drug prescription [In German]. Pneumologie 2001 Dec; 55(12):579–586.
   PubMedGoogle Scholar
• Yawn BP, Colice GL, Hodder R. Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the primary care setting. Int J Chron Obstruct Pulmon Dis; In press.
   Web of Science ®Google Scholar
• Kleinstreuer C, Zhang Z, Donohue JF. Targeted drug-aerosol delivery in the human respiratory system. Annu Rev Biomed Eng 2008; 10:195–220.
   PubMed Web of Science ®Google Scholar
• Meakin BJ, Ganderton D, Panza I, Ventura P. The effect of flow rate on drug delivery from the Pulvinal, a high-resistance dry powder inhaler. J Aerosol Med 1998 Fall; 11(3):143–152.
   PubMedGoogle Scholar
• Rubinfeld AR, Scicchitano R, Hunt A, Thompson PJ, Van Nooten A, Selroos O. Formoterol Turbuhaler as reliever medication in patients with acute asthma. Eur Respir J 2006 Apr;27(4):735-741.
   PubMed Web of Science ®Google Scholar
• Selroos O, Borgström L, Ingelf J. Use of dry powder inhalers in acute exacerbations of asthma and COPD. Ther Adv Respir Dis 2009 Apr; 3(2):81–91.
   PubMedGoogle Scholar
• Chodosh S, Flanders JS, Kesten S, Serby CW, Hochrainer D, Witek TJ, Jr. Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med 2001 Fall; 14(3):309–315.
   PubMedGoogle Scholar
• Kässner F, Hodder R, Bateman ED. A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease. Drugs 2004; 64(15):1671–1682.
   PubMed Web of Science ®Google Scholar
• Zuwallack R, De Salvo MC, Kaelin T, Bateman ED, Park CS, Abrahams R, Fakih F, Sachs P, Pudi K, Zhao Y, Wood CC. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI. Respir Med 2010 Aug; 104(8):1179–1188.
   PubMed Web of Science ®Google Scholar
• Bateman E, Singh D, Smith D, Disse B, Towse L, Massey D, Blatchford J, Pavia D, Hodder R. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis 2010; 5:197–208.
   PubMedGoogle Scholar
• Dalby R, Spallek M, Voshaar T. A review of the development of Respimat Soft Mist Inhaler. Int J Pharm 2004 Sep 28; 283(1–2):1–9.
   PubMed Web of Science ®Google Scholar
• Brand P, Hederer B, Austen G, Dewberry H, Meyer T. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis 2008; 3(4):763–770.
   PubMedGoogle Scholar
• Blau H, Mussaffi H, Mei Zahav M, Prais D, Livne M, Czitron BM, Cohen HA. Microbial contamination of nebulizers in the home treatment of cystic fibrosis. Child Care Health Dev 2007 Jul; 33(4):491–495.
   PubMed Web of Science ®Google Scholar
• Reychler G, Dupont C, Dubus JC. Disinfection of devices for nebulization: stakes, difficulties, and improvement proposals [in French]. Rev Mal Respir 2007 Dec; 24(10):1351–1361.
   PubMed Web of Science ®Google Scholar
• Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R. Guidelines for preventing health-care−associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004 Mar 26; 53(RR-3):1–36.
   PubMedGoogle Scholar
• Lareau SC, Hodder R. Teaching inhaler use in chronic obstructive pulmonary disease patients. J Am Acad Nurse Pract 2012 Feb; 24(2):113–120.
   PubMed Web of Science ®Google Scholar
• Melani AS. Inhalatory therapy training: a priority challenge for the physician. Acta Biomed 2007 Dec; 78(3):233–245.
   PubMedGoogle Scholar
• Snader TC. Managing COPD in LTC: focusing on administration of inhaled medications. Director 2004 Spring; 12(2):106–111.
   PubMedGoogle Scholar
• Epstein RM, Alper BS, Quill TE. Communicating evidence for participatory decision making. JAMA 2004 May 19; 291(19):2359–2366.
   PubMed Web of Science ®Google Scholar
• van der Palen J, Klein JJ, van Herwaarden CL, Zielhuis GA, Seydel ER. Multiple inhalers confuse asthma patients. Eur Respir J 1999 Nov; 14(5):1034–1037.
   PubMed Web of Science ®Google Scholar
• Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing 2007 Mar; 36(2):213–218.
   PubMed Web of Science ®Google Scholar
• Balzano G, Battiloro R, Biraghi M, Stefanelli F, Fuschillo S, Gaudiosi C, De Angelis E. Effectiveness and acceptability of a domiciliary multidrug inhalation treatment in elderly patients with chronic airflow obstruction: metered dose inhaler versus jet nebulizer. J Aerosol Med 2000 Spring; 13(1):25–33.
   PubMedGoogle Scholar
• Barta SK, Crawford A, Roberts CM. Survey of patients’ views of domiciliary nebuliser treatment for chronic lung disease. Respir Med 2002 Jun; 96(6):375–381.
   PubMed Web of Science ®Google Scholar
• Schürmann W, Schmidtmann S, Moroni P, Massey D, Qidan M. Respimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction. Treat Respir Med 2005; 4(1):53–61.
   PubMedGoogle Scholar
• Hass C, Engdahl K, Albert W, Setyawan J, Mateo N. Patient preferences and perceived ease of use in inhaler features: Genuair vs other iInhalers. Chest 2010; 138(4 Meeting Abstracts):484A.
   Google Scholar
• Wilson DS, Gillion MS, Rees PJ. Use of dry powder inhalers in COPD. Int J Clin Pract 2007 Dec; 61(12):2005–2008.
   PubMed Web of Science ®Google Scholar
• Van Der Palen J, Eijsvogel MM, Kuipers BF, Schipper M, Vermue NA. Comparison of the Diskus inhaler and the Handihaler regarding preference and ease of use. J Aerosol Med 2007 Spring; 20(1):38–44.
   PubMedGoogle Scholar
• Hodder R. Design and interpretation of device preference trials: Marketing tools or scientific instruments? In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, eds. Respiratory Drug Delivery X. River Grove, IL: Davis Healthcare International, 2006: 19–36.
   Google Scholar
• Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, Douglas G, Muers M, Smith D, White J. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: A systematic review of the literature. Health Technol Assess 2001; 5(26):1–149.
   PubMedGoogle Scholar
• American College of Chest Physicians. Patient instructions for inhaled devices in English and Spanish. 2006, January 1. Northbrook, IL: American College of Chest Physicians. http://www.chestnet.org/accp/patient-guides/patient-instructions-inhaled-devices-english-and-spanish (accessed 2012, June 29).
   Google Scholar